# US 2016/0251349 A1 · Solid form of pyrazolopyridine compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251349 A1
- Document ID: US20160251349A1
- Status: Published application
- Kind: A1
- Application number: 15/027,432
- Filed: 2014-10-15
- Published: 2016-09-01
- Earliest claimed: 2013-10-17
- Assignees: Sunshine Lake Pharma Co., Ltd.
- Applicants: Sunshine Lake Pharma Co., Ltd.
- Inventors: Shouzhu LIAO; Weijie FAN; Zhongqing WANG
- Web page: https://patentgrep.com/patent/US20160251349A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/10: for impotence
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A novel crystalline form or amorphous of formula (I) and preparation method thereof are disclosed in present invention, wherein the novel crystalline form is substantially pure crystalline form I, form II, form III or form IV. The novel crystalline forms disclosed herein have good solubility, low hydroscopicity and good stability at high temperature (60° C.), high humidity (RH is 90%±5%) and/or under light (4500+/−500 Lux), which benefit for storage, meet the requirements of drug stability and therefore, making formula (I) suitable for formulation preparation and with high bioavailability.

## Claims

### Claim 1

A crystalline form of compound of formula (I), wherein the crystalline form is form I, form II, form III or form IV

### Claim 2 (depends on 1)

The crystalline form of claim 1, wherein the crystalline form is form I having:
an X-ray powder diffraction pattern comprising peaks at about 25.47, 17.69 and 27.23 degrees in term of two theta, or peaks at about 25.47, 17.69, 27.23, 8.99, 6.68, 14.24, 20.27 and 19.67 degrees in term of two theta, or peaks at about 25.47, 17.69, 27.23, 8.99, 6.68, 14.24, 20.27, 19.67, 20.95, 30.76 and 20.57 degrees in term of two theta;
or an X-ray powder diffraction pattern substantially as depicted in FIG. 1.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The crystalline form of claim 1, wherein the crystalline form is form II having:
an X-ray powder diffraction pattern comprising peaks at about 25.40, 13.86, 17.21 and 22.71 degrees in term of two theta, or peaks at about 25.40, 13.86, 17.21, 22.71, 11.13, 12.56, 24.89 and 22.47 degrees in term of two theta, or peaks at about 25.40, 13.86, 17.21, 22.71, 11.13, 12.56, 24.89, 22.47, 26.04 and 29.92 degrees in term of two theta;
or an X-ray powder diffraction pattern substantially as depicted in FIG. 3.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The crystalline form of claim 1, wherein the crystalline form is form III having:
an X-ray powder diffraction pattern comprising peaks at about 25.44, 13.88, 17.23 and 15.14 degrees in term of two theta, or peaks at about 25.44, 13.88, 17.23, 15.14, 22.75, 12.60, 11.17, 9.02, 17.66, 22.52, 24.94, 17.53 and 6.68 degrees in term of two theta;
or an X-ray powder diffraction pattern substantially as depicted in FIG. 5.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The crystalline form of claim 1, wherein the crystalline form is form IV having:
an X-ray powder diffraction pattern comprising peaks at about 20.01, 27.03 and 8.21 degrees in term of two theta, or peaks at about 20.01, 27.03, 8.21, 18.15 and 27.38 degrees in term of two theta, or peaks at about 20.01, 27.03, 8.21, 18.15, 27.38, 19.22, 26.34, 29.38, 8.57, 14.45 and 7.15 degrees in term of two theta;
or an X-ray powder diffraction pattern substantially as depicted in FIG. 7.

### Claim 14 (depends on 1)

A process for preparing the crystalline form of claim 1, comprising: dissolving any solid forms of the compound of formula (I) in a good solvent to form a solution; forming crystals by reducing the temperature of the solution or removing proportion of the solvent or adding an anti-solvent to the solution; and collecting the crystal.

### Claim 15 (depends on 14)

The process of claim 14, wherein the temperature of the solution is reduced to from about −10° C. to about 40° C.

### Claim 16 (depends on 14)

The process of claim 14, wherein the crystal is formed at room temperature.

### Claim 17 (depends on 14)

The process of claim 14, wherein the method of removing proportion of the solvent comprising distillation or evaporation or any combine thereof.

### Claim 18 (depends on 14)

The process of any one claim 14, wherein the amount of the removed solvent is about 20% to about 90% with respect to the total volume of the solution.

### Claim 19 (depends on 14)

The process of any one claim 14, wherein the amount of the removed solvent is about 30% with respect to the total volume of the solution.

### Claim 20 (depends on 1)

A process for preparing the crystalline form of claim 1, comprising dissolving the compound of formula (I) in a good solvent at room temperature to form a solution, and forming crystals by adding the solution to an anti-solvent or adding an anti-solvent to the solution.

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23 (depends on 14)

The process of claim 14, wherein the good solvent or anti-solvent is selected from one or more of NMP, DMF, water, methanol, ethanol, ethylene glycol, isopropanol, n-propanol, n-butanol, tert-butanol, THF, methylene chloride, DMSO, ethyl acetate, isopropyl acetate, butanone, acetone, acetonitrile and 1,4-dioxane.

### Claim 24

(canceled)

### Claim 25 (depends on 23)

The process of claim 23, wherein the process for preparing the crystalline form I of the compound of formula (I), comprises:
adding a solution of the compound of formula (I) in DMSO with a temperature of 70° C. to 90° C. slowly to water with a temperature of 70° C. to 90° C.,
reducing the temperature to 25° C. or below after the solution was added completely, and
stirring the solution for 1 hour to 24 hour.

### Claim 26 (depends on 23)

The process of claim 23, wherein the process for preparing the crystalline form II of the compound of formula (I), comprises:
adding the compound of formula (I) to ethanol,
heating the mixture to a temperature from about 50° C. to the refluxing temperature of the solvent to form a solution,
slowly cooling the solution to room temperature, and
stirring the solution for about 1 h to 300 h and collecting the crystals.

### Claim 27 (depends on 23)

The process of claim 23, wherein the process for preparing the crystalline form III of the compound of formula (I), comprises:
mixing the compound of formula (I) with 1,4-dioxane,
heating the resulting mixture to reflux and stirring the mixture until the solid is completely dissolved to form a solution,
slowly cooling the solution to room temperature, and
stirring the solution for about 1 h to 300 h and collecting the crystals.

### Claim 28 (depends on 23)

The process of claim 23, wherein the crystalline form IV of the compound of formula (I) is formed, and wherein the good solvent is butanone.

### Claim 29

Amorphous form of compound of formula (I), wherein the X-ray powder diffraction pattern is substantially as depicted in FIG. 9.

### Claim 30 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the crystalline form of claim 1 and one or more pharmaceutically acceptable carriers or excipients.

### Claim 31

(canceled)

### Claim 32 (depends on 20)

The process of claim 20, wherein the good solvent or anti-solvent is selected from one or more of NMP, DMF, water, methanol, ethanol, ethylene glycol, isopropanol, n-propanol, n-butanol, tert-butanol, THF, methylene chloride, DMSO, ethyl acetate, isopropyl acetate, butanone, acetone, acetonitrile and 1,4-dioxane.

### Claim 33 (depends on 29)

A pharmaceutical composition comprising a therapeutically effective amount of the amorphous form of claim 29, and one or more pharmaceutically acceptable carriers or excipients.

### Claim 34 (depends on 1)

A method of treating cardiovascular diseases, thromboembolic diseases, ischemia, hypertension or treating sexual dysfunction in a patient by administering to the patient with the crystalline form of claim 1.

### Claim 35 (depends on 29)

A method of treating cardiovascular diseases, thromboembolic diseases, ischemia, hypertension or treating sexual dysfunction in a patient by administering to the patient with the amorphous form of claim 29.

### Claim 36 (depends on 30)

A method of treating cardiovascular diseases, thromboembolic diseases, ischemia, hypertension or treating sexual dysfunction in a patient by administering to the patient with the pharmaceutical composition of claim 30.

### Claim 37 (depends on 33)

A method of treating cardiovascular diseases, thromboembolic diseases, ischemia, hypertension or treating sexual dysfunction in a patient by administering to the patient with the pharmaceutical composition of claim 33.
